Curtis Jantzi, DO
Family Medicine · Kingsport, TNNPI 1740372267
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 42 manufacturers reported payments, led by Novo Nordisk at 50.1% of the total. Reporting peaked in 2023 at $15,539 and has fallen 91.6% since, to $1,313 in 2025. Among family medicine clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 705 payments — averaging $55.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$20K
- Sanofi-aventis U.S. LLC$9K
- AstraZeneca$2K
- AbbVie$2K
- Novo Nordisk AS$1K
- Janssen Research & Development, LLC$1K
- plus $4K from 36 others
Across 833 payments — averaging $1521.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$485K
- Novo Nordisk AS$344K
- AstraZeneca$197K
- AbbVie$98K
- Janssen Research & Development, LLC$75K
- Kowa Research Institute, Inc.$50K
- plus $17K from 2 others
What the payments were for
- Consulting fees$20,15251%
- Speaking & faculty fees$450%
- Travel & lodging$8,75422%
- Food & beverage$10,44427%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$8,730
- BREZTRI$230
- AIRSUPRA$230
- FARXIGA$230
How this compares
$39,407 in reported general payments places this provider in the 95th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 166 | $191,360 |
| EliquisApixaban | 193 | $167,088 |
| MounjaroTirzepatide | 86 | $101,921 |
| TrulicityDulaglutide | 67 | $93,697 |
| XareltoRivaroxaban | 77 | $88,219 |
| Tresiba Flextouch U-200Insulin Degludec | 57 | $80,988 |
| FarxigaDapagliflozin Propanediol | 70 | $76,105 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 71 | $69,989 |
| JardianceEmpagliflozin | 54 | $64,662 |
| XifaxanRifaximin | 11 | $35,901 |
| Tresiba Flextouch U-100Insulin Degludec | 40 | $30,119 |
| Spiriva HandihalerTiotropium Bromide | 33 | $30,009 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 33 | $27,546 |
| LinzessLinaclotide | 23 | $27,309 |
| EntrestoSacubitril/Valsartan | 22 | $26,546 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $101 | $195,618153 claims |
| Novo NordiskOzempic | $19,733 | $191,360166 claims |
| PfizerEliquis | $407 | $167,088193 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $2,281 | $108,761119 claims |
| Johnson & JohnsonXarelto | $153 | $88,21977 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $891 | $86,59692 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $112 | $71,08465 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $178 | $35,90111 claims |
| AbbVieLinzess, Savella | $1,669 | $33,22334 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $9,209 | $27,54633 claims |
| NovartisEntresto | $227 | $26,54622 claims |
| Astellas Pharma US IncMyrbetriq | $510 | $18,12123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Kingsport
- Warren JonesKingsport$27K
- Emily HubbsKingsport$19K
- Shelton HagerKingsport$14K
- Kevin DennisFranklin$354K
- Charolette JacksonBartlett$162K
- Keren HolmesNashville$58K
- Kabir Harricharan SinghNewport$49K
- Khaisha GistAntioch$49K
- Jerry PunchKnoxville$45K
- Christopher HollowayAntioch$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.